Placeholder Banner

BIO Comments on ICH Q12 Draft Guideline

December 12, 2018

BIO submitted comments on the Food and Drug Administration (FDA) Draft Guideline, Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management.

BIO appreciates FDA’s commitment to harmonization of regulatory concepts across regional Health Authorities through the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Harmonization of critical regulatory concepts is important to ensuring a consistent and predictable regulatory environment and gives sponsors confidence their drug development program will be generally accepted within different regions. BIO believes that the concepts in Q12 are important and warrant broad recognition across the globe.

BIO is encouraged by the work of the ICH Q12 working group but has concerns about implementation. BIO provides general and specific comments to strengthen and clarify the guideline. The comments cover topics including regional variability in implementation, Established Conditions (ECs), Post-Approval Change Management Protocol (PACMP), Product Lifecycle Management (PLCM), and more.

Download Full Comments Below
2018-12-15 BIO Comments On ICH Q12 FINAL
Read full comment letter below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
The Biotechnology Innovation Organization (“BIO”) would like to submit the following comments regarding FDA’s recent proposal to implement aspects of the Canadian importation provisions of Section 804 of the Food Drug & Cosmetics Act (“FD&C…